Howard Burris 3rd
Overview
Explore the profile of Howard Burris 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
970
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fracasso P, Burris 3rd H, Arquette M, Govindan R, Gao F, Wright L, et al.
Clin Cancer Res
. 2007 Feb;
13(3):986-93.
PMID: 17289894
Purpose: This phase 1 study evaluated the pharmacokinetic and pharmacodynamic effects of cetuximab on patients with epithelial malignancies. Experimental Design: Following a skin and tumor biopsy, patients with advanced epithelial...
12.
Twelves C, Wong A, Nowacki M, Abt M, Burris 3rd H, Carrato A, et al.
N Engl J Med
. 2005 Jul;
352(26):2696-704.
PMID: 15987918
Background: Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment...
13.
Spector N, Xia W, Burris 3rd H, Hurwitz H, Dees E, Dowlati A, et al.
J Clin Oncol
. 2005 Feb;
23(11):2502-12.
PMID: 15684311
Purpose: This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients with advanced ErbB1 and/or ErbB2-overexpressing solid malignancies. Patients And Methods:...
14.
Burris 3rd H, Yardley D, Jones S, Houston G, Broome C, Thompson D, et al.
J Clin Oncol
. 2004 May;
22(9):1621-9.
PMID: 15117984
Purpose: To determine the response rate of trastuzumab as first-line therapy in patients with HER-2 overexpressing metastatic breast cancer. To assess the feasibility and toxicity of weekly paclitaxel/carboplatin with or...